Alitretinoin

阿利维A酸

Report date: 2022/08/29 15:13:18

Base Information

Drug NameAlitretinoin
Drug Alias Name阿利维甲酸Alitretinoinum9-cis-retinoic acidPanrexinPanretin +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRetinoic acid receptor gamma agonistsRetinoic acid receptor alpha agonistsRetinoid X receptor alpha agonists +[6] 
TargetsRetinoid X receptor gammaRetinoic acid receptor betaRetinoid X receptor alpha +[6] 
Therapy Area/IndicationsPsoriasisHand DermatosesEczema +[7] 
Global Approved IndicationsSarcoma, Kaposi
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1999/02/02
Country/TerritoryCanadaUnited StatesPoland +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAdvanz Pharma Ltd
Inactive CompaniesAnderson Clinical ResearchStiefel LaboratoriesLigand Pharmaceuticals Inc +[7] 
Active IndicationsSarcoma, Kaposi
Inactive IndicationsPsoriasisHand DermatosesEczema +[6] 

Other Information

ATC CodeD11AH04L01XF02
Related LinksWikipediaDrugBankKEGG